With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
A regimen consisting of only two drugs, the integrase inhibitor dolutegravir (Tivicay) and the NNRTI rilpivirine (Edurant), held up well as a maintenance approach in people with HIV who switched from more complex regimens.
Though it may not be the riskiest aspect of HIV cure research, ATI (analytical treatment interruption) is among the more controversial topics in the field right now, noted Karine Dubé, DrPH, of the University of North Carolina at Chapel Hill, at the ...
Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small proof-of-concept study present...
Paul Sax, M.D., breaks down another HIV treatment switching study -- this one from IDWeek 2015 -- the results of which supported switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir (Prezista) for treatment-experien...
An 18-year-old female has been able to maintain an undetectable viral load for more than 12 years after interrupting early antiretroviral treatment, according to a study presented at IAS 2015.
A study showed viral control in the great majority of youth who took their regimen for five days but then skipped two, which may offer younger patients a novel way to keep HIV under control while addressing common adherence issues.
Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.